Company: SXI
Filing Date: 2025-08-04
Form Type: 10-K
Source: 0001437749-25-024450
Chunk: 1142

Company: STANDEX INTERNATIONAL CORP/DE/
Filing Date: 2025-08-04
Form: 10-K
Item: Item 1A
Chunk 1142
---
19,000

     (8.1%)

     19,000

     17,109

     11.1%

      Operating income margin 

     24.1%

     27.6%

     27.6%

     22.8%

Net sales in fiscal year 2025 increased by $3.4 million, or 5.0% when compared to the prior year, due to benefit from the Custom Biogenic Systems acquisition, mostly offset by an organic decline from lower demand at academic and research institutions that were impacted by NIH funding cuts. 

Income from operations in fiscal year 2025 decreased by $1.5 million, or 8.1%, when compared to the prior year due to organic decline partially offset by contribution from the acquisition and price and productivity initiatives.

      21

Net sales in fiscal year 2024 decreased by $6.0 million, or 8.0% when compared to the prior year. Net sales decreased reflecting general market softness, including purchases by retail pharmacies.

Income from operations in fiscal year 2024 increased $1.9 million or 11.1%, when compared to the prior year. Operating income increase reflects productivity initiatives and lower freight costs, partially offset by lower volume. 

Engraving

      2025 compared to 2024 

      2024 compared to 2023 

      (in thousands except 

      % 

      % 

      percentages) 
      
      2025 

      2024 

      Change 

      2024 

      2023 

      Change 

      Net sales 
      
     $128,360

     $150,685

      (14.8%) 

     $150,685

     $152,067

      (0.9%) 

      Income from operations 
      
     17,647

     26,708

      (33.9%) 

     26,708

     25,462

      4.9% 

      Operating income margin 
      
      13.7% 

      17.7% 

      17.7% 

      16.7% 

Net sales in fiscal year 2025 decreased by $22.3 million, or 14.8%, compared to the prior year. Organic sales decreased by